Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Merck
AstraZeneca
Dow
McKinsey

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,776,015

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,776,015 protect, and when does it expire?

Patent 7,776,015 protects OTREXUP and is included in one NDA.

This patent has thirteen patent family members in eight countries.

Summary for Patent: 7,776,015
Title:Needle assisted jet injector
Abstract: A jet injection device with a fluid chamber in a housing member for holding about 0.02 ml to about 3 ml of a medicament. An injection-assisting needle has an injection end that extends from the housing for inserting into a patient to a depth of up to about 5 mm. A force-generating source is configured to apply a pressure reaching about 100-1000 psi to the medicament in the chamber to expel the medicament through the injecting end of the needle.
Inventor(s): Sadowski; Peter L. (Woodbury, MN), Deboer; David M. (Brighton, MI), Berman; Claude L. (Ypsilanti, MI), Lesch, Jr.; Paul R. (Lexington, MI), Holland; Margaret L. (Rochester, NY)
Assignee: Antares Pharma Inc. (Minneapolis, MN)
Application Number:11/002,687
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,776,015
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 7,776,015

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-004 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Merck
Boehringer Ingelheim
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.